Other

Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Eberhard-karls-universitaet Tuebingen Universitaetsklinikum

Bossow, Sascha

Bitzer, Michael

Lange, Sebastian

Lampe, Johanna

Zimmermann, Martina

Berchtold, Susanne

Lauer, Ulrich M.

Neubert, Wolfgang J.

Wolfgang J Neubert

Sascha Bossow

Michael Bitzer

Ulrich Manfred Lauer

Susanne Berchtold

Sebastian Lange

Martina Zimmermann

Johanna Lampe

Sorin Armeanu-Ebinger

Martina Schell

Sabine Schlecht

Ulrich M Lauer

A genome-replication-deficient and transcription/competent negative/strand RNA virus, which can be used for the expression of transgenes and in particular for the area of vaccine development. In particular, a recombinant Sendia virus containing a viral genome with a mutation in the gene P, which leads to loss of capacity for replication without loss of capacity for secondary transcription, and at least one sequence coding for a heterologous gene product. Furthermore, a nucleocapsid of the Sendai virus, a genome of the Sendai virus, a DNA molecule that codes for the genome and/or antigenome of the Sendai virus. One aspect is a pharmaceutical composition containing the Sendai virus, the nucleocapsid, or the viral genome as active substance, and a medical use thereof, especially as a vaccine.

Replication-deficient RNA viruses as vaccines

The present invention relates to a genetically modified Paramyxovirus, a pharmaceutical composition comprising this paramyxovirus, the use of a genetically modified Paramyxovirus for the therapeutic and/or prophylactic treatment of a tumor disease, and a method for the production of a pharmaceutical composition for the therapeutic or prophylactic treatment of a tumor disease.

Genetically modified paramyxovirus for treatment of tumor diseases

The present invention pertains to a pharmaceutical composition comprising a recombinant measles virus encoding a suicide gene for use in the treatment of malignant cells with primary or secondary resistances against an oncolytic measles virus without suicide gene activity. Further, the present invention pertains to a recombinant measles virus based on measles vaccine strain Schwarz encoding a suicide gene, which comprises a fusion of a cytosine deaminase, particularly yeast cytosine deaminase, and a uracil phosphoribosyltransferase, particularly yeast uracil phosphoribosyltransferase, to a method and a kit for preparing the recombinant measles virus as claimed herein.

Oncolytic measles virus

Growing community of inventors

Greifenberg, Germany

Wolfgang J Neubert